-
1.发明申请公开(公告)号：US20200277364A1
公开(公告)日：2020-09-03
申请号：US16645877
申请日：2018-09-26
发明人： Stephen Yoo , Rickey Robert Reinhardt , Sherri Van Everen , Karen Fran Kozarsky , Curran Matthew Simpson , Zhuchun Wu , Peter Anthony Campochiaro , Jikui Shen , Kun Ding
摘要： Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
-
2.发明公开公开(公告)号：US20240254214A1
公开(公告)日：2024-08-01
申请号：US18360073
申请日：2023-07-27
发明人： Stephen Yoo , Rickey Robert Reinhardt , Sherri Van Everen , Karen Fran Kozarsky , Curran Matthew Simpson , Zhuchun Wu , Peter Anthony Campochiaro , Jikui Shen , Kun Ding
IPC分类号： C07K16/22 , A61F9/00 , A61K9/00 , A61M25/00 , A61M25/01 , A61P27/02 , C12N7/00 , C12N15/86 , A61K39/00 , A61K48/00
CPC分类号： C07K16/22 , A61F9/0017 , A61K9/0019 , A61K9/0048 , A61M25/0084 , A61M25/0194 , A61P27/02 , C12N7/00 , C12N15/86 , A61K2039/505 , A61K48/00 , A61M2025/0089 , A61M2210/0612 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C12N2750/14143 , C12N2750/14171
摘要： Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”) —such as, e.g., a fully human-glycosylated (HuGly) anti-h VEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
-
3.发明公开公开(公告)号：US20240050537A1
公开(公告)日：2024-02-15
申请号：US18480172
申请日：2023-10-03
申请人： REGENXBIO Inc.
IPC分类号： A61K38/47 , A61P25/28 , A61K31/365 , A61K31/436 , A61K31/573 , A61K48/00
CPC分类号： A61K38/47 , A61P25/28 , A61K31/365 , A61K31/436 , A61K31/573 , A61K48/005 , A61K48/0083 , C12Y302/01076
摘要： Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) α-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).
-
公开(公告)号：US11613739B2
公开(公告)日：2023-03-28
申请号：US16604427
申请日：2018-04-13
申请人： REGENXBIO Inc.
摘要： Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
-
5.发明申请公开(公告)号：US20230057519A1
公开(公告)日：2023-02-23
申请号：US17704170
申请日：2022-03-25
申请人： REGENXBIO Inc.
发明人： Curran Matthew Simpson , Stephen Yoo , Karen Fran Kozarsky , Rickey Robert Reinhardt , Laura A. Coruzzi
摘要： Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
-
6.发明申请公开(公告)号：US20210275647A1
公开(公告)日：2021-09-09
申请号：US17260732
申请日：2019-07-17
申请人： REGENXBIO INC.
IPC分类号： A61K38/47 , A61K48/00 , A61K31/436 , A61K31/343 , A61K31/573 , A61K35/761 , A61P3/00 , C12N7/00
摘要： Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) α-L-iduronidase (ID-UA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).
-
公开(公告)号：US20200149019A1
公开(公告)日：2020-05-14
申请号：US16604427
申请日：2018-04-13
申请人： REGENXBIO Inc.
摘要： Compositions and methods are described for the delivery of recombinant human iduronate-2-sulfatase (IDS) produced by human neuronal or glial cells to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis II (MPS II).
-
8.发明申请公开(公告)号：US20190211091A1
公开(公告)日：2019-07-11
申请号：US16361884
申请日：2019-03-22
申请人： REGENXBIO Inc.
发明人： Curran Matthew Simpson , Stephen Yoo , Karen Fran Kozarsky , Rickey Robert Reinhardt , Laura A. Coruzzi
CPC分类号： C07K16/22 , A61K9/0048 , A61K48/005 , A61K48/0075 , A61K2039/505 , A61P27/02 , C07K2317/24 , C07K2317/41 , C07K2317/55 , C07K2317/622 , C12N15/86 , C12N2750/14143 , C12N2830/42 , C12N2830/50 , C12N2840/203
摘要： Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.016 秒)
